You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Eribulin

Showing 1 - 25 of 212
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Eribulin mesylate injection、Pertuzumab、Trastuzumab
  • Guanzhou, Guangdong, China
    LI YuDong
Jul 13, 2023

Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)

Recruiting
  • Refractory Solid Tumors
  • Eribulin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2023

Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)

Not yet recruiting
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • (no location specified)
Jan 31, 2023

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (MEN1611, Eribulin)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • (no location specified)
Apr 12, 2023

Eribulin-Based Regimen Versus Other Chemotherpy in

Active, not recruiting
  • Breast Cancer
  • Eribulin-Based Regimen
  • +2 more
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Jul 18, 2023

Breast Cancer Trial in Tampa (Eribulin, Carboplatin)

Completed
  • Breast Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Oct 28, 2022

Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult Trial in Taipei (Eribulin, Lenvatinib)

Active, not recruiting
  • Leiomyosarcoma
  • +3 more
  • Taipei, Taiwan
  • +1 more
Dec 27, 2022

Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,

Active, not recruiting
Has Results
  • Inflammatory Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Eribulin
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 28, 2022

Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

Recruiting
  • Triple Negative Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022

HER2 Negative Breast Cancer Trial in Zhenzhou (Eribulin plus Tucidinostat)

Not yet recruiting
  • HER2 Negative Breast Cancer
  • Eribulin plus Tucidinostat
  • Zhenzhou, China
    Henan Cancer Hospital
May 26, 2022

Metastatic Breast Cancer Trial in Changsha (Eribulin Mesylate, Anlotinib)

Recruiting
  • Metastatic Breast Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
May 4, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Terminated
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Bintrafusp Alfa
  • Eribulin Mesylate
  • Houston, Texas
  • +1 more
Oct 27, 2022

Liposarcoma, Malignant Abdominal Tumor, Malignant Retroperitoneal Tumor Trial in Portland (drug, radiation, other, procedure)

Recruiting
  • Liposarcoma
  • +5 more
  • Eribulin Mesylate
  • +5 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Oct 17, 2022

Breast Cancer Trial (Tucatinib, Eribulin, Trastuzumab)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jul 12, 2022

TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Eribulin
  • anti-PD-1 antibody
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
May 29, 2022

Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma Trial in Houston

Recruiting
  • Breast Inflammatory Carcinoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2022

Metastatic Breast Cancer Trial in Italy (Eribulin Mesylate, Capecitabine)

Active, not recruiting
  • Metastatic Breast Cancer
  • Brescia, Italy
  • +24 more
Apr 18, 2023

Solid Tumor Trial in Buffalo (Eribulin ORA)

Recruiting
  • Solid Tumor
  • Eribulin ORA
  • Buffalo, New York
    Roswell Park Cancer Institute
Feb 15, 2022

Breast Cancer, Metastatic Triple-Negative Breast Cancer Trial in United States (Eribulin, SDX-7320, Placebo)

Recruiting
  • Breast Cancer
  • Metastatic Triple-Negative Breast Cancer
  • Eribulin
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Oct 4, 2022

Angiosarcoma, Epithelioid Hemangioendothelioma Trial in Boston (Eribulin)

Recruiting
  • Angiosarcoma
  • Epithelioid Hemangioendothelioma
  • Eribulin
  • Boston, Massachusetts
  • +1 more
Feb 14, 2022

Metastatic Malignant Tumor in the Adult Brain, Primary Brain Tumor Trial in Duarte (procedure, drug, other)

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Adult Brain
  • Primary Brain Tumor
  • Therapeutic Conventional Surgery
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Mar 16, 2022

HER2-negative Breast Cancer Trial (Gemcitabine combined with eribulin)

Not yet recruiting
  • HER2-negative Breast Cancer
  • Gemcitabine combined with eribulin
  • (no location specified)
Mar 2, 2022

Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative Trial in Duarte, Rancho Cucamonga, South Pasadena

Completed
Has Results
  • Estrogen Receptor Negative
  • +4 more
  • Duarte, California
  • +2 more
Jun 6, 2022

Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Bronx (Rebastinib,

Terminated
  • Breast Cancer
  • +4 more
  • Bronx, New York
    Montefiore Medical Center
Mar 23, 2022

Breast Cancer Trial in Boston (Eribulin Mesylate, Pembrolizumab)

Active, not recruiting
Has Results
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
Apr 18, 2022